Knocking out ALKBH5 in glioma or targeting it with IOX1 reduces the expression of the PD-L1 protein, inhibits tumor growth, extends the survival of mice, and enhances these effects of PD-1 blockade therapy (105). Here, ALKBH5 is linked to neoplasm.